| 13.72 -0.235 (-1.68%) | 01-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18 | 1-year : | 19.44 |
| Resists | First : | 15.41 | Second : | 16.64 |
| Pivot price | 13.9 |
|||
| Supports | First : | 13.4 | Second : | 11.15 |
| MAs | MA(5) : | 13.85 |
MA(20) : | 14.24 |
| MA(100) : | 16.06 |
MA(250) : | 13.53 | |
| MACD | MACD : | -0.6  |
Signal : | -0.7 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 21 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 20.89 | Low : | 7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMRN ] has closed above bottom band by 26.8%. Bollinger Bands are 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.35 - 14.42 | 14.42 - 14.49 |
| Low: | 13.4 - 13.49 | 13.49 - 13.57 |
| Close: | 13.49 - 13.63 | 13.63 - 13.76 |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Wed, 24 Dec 2025
Zacks Research Analysts Lower Earnings Estimates for Amarin - MarketBeat
Sun, 09 Nov 2025
Amarin (NASDAQ: AMRN) shares REDUCE-IT aspirin analysis showing 36% fewer total CV events - Stock Titan
Sat, 01 Nov 2025
Amarin Corporation plc (NASDAQ:AMRN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.33 - Yahoo Finance
Fri, 31 Oct 2025
Amarin Corporation’s Financial Health at Risk Amid Global Trade Uncertainties - The Globe and Mail
Thu, 30 Oct 2025
Amarin Corporation plc (NASDAQ:AMRN) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 30 Oct 2025
Amarin Corp PLC (AMRN) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 376 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 20.3 (%) |
| Shares Short | 416 (K) |
| Shares Short P.Month | 371 (K) |
| EPS | -4.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.05 |
| Profit Margin | -38.1 % |
| Operating Margin | -3.5 % |
| Return on Assets (ttm) | -2.5 % |
| Return on Equity (ttm) | -17.5 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 5.99 |
| Sales Per Share | 10.9 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -3.25 |
| PEG Ratio | 0 |
| Price to Book value | 0.61 |
| Price to Sales | 1.25 |
| Price to Cash Flow | -12.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|